Last reviewed · How we verify

Endometrial carcinoma progressing after chemotherapy — Treatment Landscape & Competitive Intelligence

Endometrial carcinoma progressing after chemotherapy (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endometrial carcinoma progressing after chemotherapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lenvima LENVATINIB Eisai Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret 2015-01-01
Pembrolizuma Pembrolizuma Memorial Sloan Kettering Cancer Center Programmed cell death protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Eisai · 1 drug in Endometrial carcinoma progressing after chemotherapy
  2. Memorial Sloan Kettering Cancer Center · 1 drug in Endometrial carcinoma progressing after chemotherapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endometrial carcinoma progressing after chemotherapy:

Cite this brief

Drug Landscape (2026). Endometrial carcinoma progressing after chemotherapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endometrial-carcinoma-progressing-after-chemotherapy. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing